:::I'm not sure sulfonylureas are the best comparator, as they have been suspected of increasing CV mortality at least since I worked in the diabetes area in the early 1990s. Not sure if that suspicion has waned. Back then it was attributed to their property of increasing hyperinsulinemia, which was part of what set off the search for insulin sensitizers (some of which have been even worse).  

 :::I guess my point is just that since none or almost none of the anti hyperglycemia drugs reduces CV mortality, we should adopt common language and not leave the impression that particular agents are uniquely lacking in CV benefits.  

 :::What would you like to do here? I'd vote for at least adding the phrase that "few if any other anti hyperglycemic drugs improve CV outcomes". Of course I'll have to run down the references for this.